Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Other Non Operating Income (2018 - 2025)

Regenxbio has reported Other Non Operating Income over the past 11 years, most recently at $18000.0 for Q4 2025.

  • Quarterly results put Other Non Operating Income at $18000.0 for Q4 2025, down 78.31% from a year ago — trailing twelve months through Dec 2025 was $83000.0 (down 52.3% YoY), and the annual figure for FY2025 was $83000.0, down 52.3%.
  • Other Non Operating Income for Q4 2025 was $18000.0 at Regenxbio, down from $19000.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for RGNX hit a ceiling of $554000.0 in Q2 2021 and a floor of -$141000.0 in Q4 2023.
  • Median Other Non Operating Income over the past 5 years was $33000.0 (2021), compared with a mean of $67150.0.
  • Biggest five-year swings in Other Non Operating Income: soared 305.26% in 2022 and later plummeted 283.12% in 2023.
  • Regenxbio's Other Non Operating Income stood at $19000.0 in 2021, then skyrocketed by 305.26% to $77000.0 in 2022, then plummeted by 283.12% to -$141000.0 in 2023, then surged by 158.87% to $83000.0 in 2024, then plummeted by 78.31% to $18000.0 in 2025.
  • The last three reported values for Other Non Operating Income were $18000.0 (Q4 2025), $19000.0 (Q3 2025), and $21000.0 (Q2 2025) per Business Quant data.